AnaptysBio, Inc.
Status: Publicly traded
Direct answer
AnaptysBio, Inc. is publicly traded on NASDAQ under the ticker ANAB.
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease...
Can you invest in AnaptysBio, Inc.?
Yes. AnaptysBio, Inc. is publicly traded on NASDAQ under the ticker ANAB.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for AnaptysBio, Inc.
Detailed equity research is provided by MarketSnap.